SERPINA1 and alpha 1-antitrypsin deficiency: In conclusion, our results show that fibrinopeptide AαVal541 may serve as a biochemical footprint for assessing the efficacy of in vivo inhibition of proteinase 3 activity in AATD patients receiving intravenous AAT augmentation therapy.